Search Results - "Vogelvang, TE"

Emerging selective estrogen receptor modulators : Special focus on effects on coronary heart disease in postmenopausal women by VOGELVANG, Tatjana Elène, VAN DER MOOREN, Marius Jan, MIJATOVIC, Velja, KENEMANS, Peter

“…Menopause, regardless of age at onset, is associated with a marked increase in coronary heart disease (CHD) risk. On the basis of epidemiological studies that…”
Get full text

HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo‐controlled study in postmenopausal women by VOGELVANG, T. E., LEURS, J. R., MIJATOVIC, V., WILLEMSE, J., VAN DER MOOREN, M. J.

Get full text

Recurrence of pre‐eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta‐analysis by Brouwers, L, Meiden‐van Roest, AJ, Savelkoul, C, Vogelvang, TE, Lely, AT, Franx, A, Rijn, BB

“…Background Women with a history of hypertensive disorders, including pre‐eclampsia, during pregnancy have a two‐ to‐five‐fold increased risk of cardiovascular…”
Get full text

Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac function by Vogelvang, Tatjana E, van der Mooren, Marius J, Kamp, Otto, Mijatovic, Velja, Visser, Cees A, Kenemans, Peter

“…To investigate the effects of transdermal 17 beta-estradiol (E(2)) compared with oral unopposed as well as opposed E(2) on echocardiographic parameters of left…”
Get more information

SARS‐CoV‐2 infection in pregnancy during the first wave of COVID‐19 in the Netherlands: a prospective nationwide population‐based cohort study (NethOSS) by Overtoom, EM, Rosman, AN, Zwart, JJ, Vogelvang, TE, Schaap, TP, Akker, T, Bloemenkamp, KWM

“…Objective To describe characteristics, risk factors and maternal, obstetric and neonatal outcomes of pregnant women infected with severe acute respiratory…”
Get full text

HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women by Vogelvang, Tatjana E, Mijatovic, Velja, Kenemans, Peter, Teerlink, Tom, van der Mooren, Marius J

“…To investigate the short-term effects of HMR 3339 in comparison with raloxifene and placebo on cardiovascular risk factors. A multicenter, randomized,…”
Get more information

The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: A randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women by Vogelvang, Tatjana E., Mijatovic, Velja, Kenemans, Peter, Emeis, Jef J., Heijst, Johannes A., van der Mooren, Marius J.

“…To investigate the short-term effects of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis. In a multicenter,…”
Get full text

Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women by Vogelvang, Tatjana E., Mijatovic, Velja, Kenemans, Peter, Schalkwijk, Casper G., van der Mooren, Marius J.

“…We investigated the 12-week effects of 3 doses of HMR 3339, a novel selective estrogen receptor modulator, in comparison with raloxifene and placebo, on plasma…”
Get full text

A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine by Smolders, Raimond G.V, Vogelvang, Tatjana E, Mijatovic, Velja, Marchien van Baal, W, Neele, Simone J.M, Netelenbos, J.Coen, Kenemans, Peter, van der Mooren, Marius J

“…Objectives: Lipoprotein(a) (Lp(a)) and homocysteine (Hcy) are independent cardiovascular risk factors, which have been shown to be lowered by hormone…”
Get full text

Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: Two randomized, placebo-controlled, 2-year studies by Vogelvang, Tatjana E., Mijatovic, Velja, Kamp, Otto, Netelenbos, J.Coen, Neele, Simone J.M., Pines, Amos, Kenemans, Peter, van der Mooren, Marius J.

“…Objective: Our purpose was to investigate the long-term effects of raloxifene, compared with opposed and unopposed estrogen replacement therapy, on…”
Get full text

Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women by Vogelvang, Tatjana E., Leurs, Judith R., van der Mooren, Marius J., Mijatovic, Velja, Hendriks, Dirk F., Neele, Simone J.M., Netelenbos, J. Coen, Kenemans, Peter

“…OBJECTIVEThe aim of this study was to compare the long-term effects of two dosages of raloxifene with oral hormone therapy (HT; conjugated equine estrogens…”
Get full text

Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women by Vogelvang, Tatjana E., Mijatovic, Velja, van der Mooren, Marius J., Pinsdorf, Ursula, von Bergmann, Klaus, Netelenbos, J. Coen, Lütjohann, Dieter

“…To compare the 2-year effects of raloxifene (Rlx) with oral postmenopausal hormone therapy (HT) on serum markers of brain and whole-body cholesterol…”
Get full text